Inactive Instrument

Ceapro Inc. Stock

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Dynamic Chart
Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly MT
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction. CI
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger MT
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Aeterna Zentaris Finalizes Some Details for Ceapro Merger MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro MT
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co MT
More news
Managers TitleAgeSince
Chief Executive Officer 70 06-12-31
Director of Finance/CFO - 15-05-04
Chief Tech/Sci/R&D Officer - 23-04-30
Members of the board TitleAgeSince
Chief Executive Officer 70 06-12-31
Director/Board Member - 15-04-26
Director/Board Member 61 14-11-19
More insiders
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
More about the company